Published in N Engl J Med on May 04, 2014
Efficacy and Safety of Daclatasvir Plus Asunaprevir in Chronic Hepatitis C (ESDAC) | NCT02639585
Effect Of DAAs For Treatment Of HCV On Normal Kidney | NCT03296930
Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy. Clin Infect Dis (2015) 2.08
Hepatitis C. Lancet (2015) 1.95
An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol Hepatol (2015) 1.86
How Generalizable Are the Results From Trials of Direct Antiviral Agents to People Coinfected With HIV/HCV in the Real World? Clin Infect Dis (2016) 1.63
Viekira Pak (Ombitasvir, Paritaprevir, and Ritonavir Tablets; Dasabuvir Tablets): All-Oral Fixed Combination Approved for Genotype 1 Chronic Hepatitis C Infection. Am Health Drug Benefits (2015) 1.37
In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A. Antimicrob Agents Chemother (2014) 1.23
In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450. Antimicrob Agents Chemother (2014) 1.20
Therapy of hepatitis C--back to the future. N Engl J Med (2014) 1.17
KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol (2016) 1.15
Treatment Options in Hepatitis C. Dtsch Arztebl Int (2017) 1.10
Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. Hepatology (2016) 1.10
Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. Hepatology (2015) 1.09
In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor. Antimicrob Agents Chemother (2014) 1.05
Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting Antivirals. Hepat Mon (2016) 1.02
Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review. Can J Gastroenterol Hepatol (2014) 1.00
Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis. Ann Intern Med (2014) 0.99
Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy. Clin Pharmacokinet (2016) 0.99
Advances in hepatitis C therapy: What is the current state - what come's next? World J Hepatol (2016) 0.98
Chronic hepatitis C: This and the new era of treatment. World J Hepatol (2016) 0.98
Ledipasvir/Sofosbuvir (harvoni): improving options for hepatitis C virus infection. P T (2015) 0.98
The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment. Therap Adv Gastroenterol (2015) 0.97
Interferon-free combination therapies for the treatment of hepatitis C: current insights. Hepat Med (2015) 0.97
APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Int (2016) 0.96
Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens. Clin Infect Dis (2015) 0.96
Enhancing our understanding of current therapies for hepatitis C virus (HCV). Curr HIV/AIDS Rep (2015) 0.94
Population pharmacokinetic modeling of plasma and intracellular ribavirin concentrations in patients with chronic hepatitis C virus infection. Antimicrob Agents Chemother (2015) 0.93
Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System. Gastroenterology (2016) 0.93
Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade. World J Hepatol (2015) 0.91
Primary Care Physician Perspectives on Hepatitis C Management in the Era of Direct-Acting Antiviral Therapy. Dig Dis Sci (2016) 0.91
Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir. Antimicrob Agents Chemother (2015) 0.90
Pharmacokinetics and tolerability of paritaprevir, a direct acting antiviral agent for hepatitis C virus treatment, with and without ritonavir in healthy volunteers. Br J Clin Pharmacol (2016) 0.90
New approaches in the treatment of hepatitis C. World J Gastroenterol (2016) 0.90
Treatment of chronic HCV with sofosbuvir and simeprevir in patients with cirrhosis and contraindications to interferon and/or ribavirin. Am J Gastroenterol (2015) 0.89
Assessment of drug-drug interactions between daclatasvir and methadone or buprenorphine-naloxone. Antimicrob Agents Chemother (2015) 0.89
Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals. Viruses (2015) 0.89
Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights. Nat Rev Gastroenterol Hepatol (2016) 0.88
Evaluation of Drug-Drug Interactions between Direct-Acting Anti-Hepatitis C Virus Combination Regimens and the HIV-1 Antiretroviral Agents Raltegravir, Tenofovir, Emtricitabine, Efavirenz, and Rilpivirine. Antimicrob Agents Chemother (2016) 0.87
Hepatitis C cirrhosis: New perspectives for diagnosis and treatment. World J Hepatol (2015) 0.87
New Direct-Acting Antiviral Therapies for Treatment of Chronic Hepatitis C Virus Infection. Gastroenterol Hepatol (N Y) (2015) 0.86
Resistance-Associated NS5A Variants of Hepatitis C Virus Are Susceptible to Interferon-Based Therapy. PLoS One (2015) 0.86
Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients. PLoS One (2015) 0.86
Predictive factors associated with hepatitis C antiviral therapy response. World J Hepatol (2015) 0.86
SASLT guidelines: Update in treatment of Hepatitis C virus infection. Saudi J Gastroenterol (2016) 0.85
Drug-Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers. Clin Pharmacokinet (2016) 0.85
Dimension of chronic hepatitis C virus in HIV-infected patients in the interferon-free era: an overview from south Spain. Eur J Clin Microbiol Infect Dis (2015) 0.84
Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti-Hepatitis C Virus Therapy in Patients With Advanced Liver Disease. Clin Infect Dis (2015) 0.84
Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis. PLoS One (2014) 0.84
Recent Advances in Antiviral Therapy for Chronic Hepatitis C. Mediators Inflamm (2016) 0.83
Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for chronic hepatitis C. Aust Prescr (2016) 0.83
CIHR Canadian HIV Trials Network Co-Infection and Concurrent Diseases Core: Updated Canadian guidelines for the treatment of hepatitis C infection in HIV-hepatitis C coinfected adults. Can J Infect Dis Med Microbiol (2015) 0.83
Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents. Am J Gastroenterol (2016) 0.82
Boceprevir Plus Peginterferon Alfa-2a/Ribavirin in Treatment-Naïve Hepatitis C Virus Genotype 1 Patients: International Phase IIIb/IV TriCo Trial. Infect Dis Ther (2016) 0.81
Consequences of inaccurate hepatitis C virus genotyping on the costs of prescription of direct antiviral agents in an Italian district. Clinicoecon Outcomes Res (2016) 0.81
All-oral interferon-free treatments: The end of hepatitis C virus story, the dream and the reality. World J Hepatol (2015) 0.81
Chronic Hepatitis C Virus Infection: A Review of Current Direct-Acting Antiviral Treatment Strategies. N Am J Med Sci (Boston) (2016) 0.81
Recent advances in management of the HIV/HCV coinfected patient. Future Virol (2016) 0.81
New era for management of chronic hepatitis C virus using direct antiviral agents: A review. J Adv Res (2014) 0.80
Hepatitis C treatment in the elderly: New possibilities and controversies towards interferon-free regimens. World J Gastroenterol (2015) 0.80
Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients. Value Health (2016) 0.80
Global epidemiology and burden of HCV infection and HCV-related disease. Nat Rev Gastroenterol Hepatol (2016) 0.80
Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review. Ann Intern Med (2017) 0.79
Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. Hepatology (2017) 0.79
Cost-effectiveness of new antiviral regimens for treatment-naïve U.S. veterans with hepatitis C. Hepatology (2015) 0.79
Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia. Liver Int (2015) 0.79
New prospects for the treatment and prevention of hepatitis C in children. Curr Opin Pediatr (2016) 0.79
ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection. PLoS One (2015) 0.79
Hepatitis C in non-hepatic solid organ transplant candidates and recipients: A new horizon. World J Gastroenterol (2016) 0.78
Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12. World J Gastroenterol (2016) 0.78
Management of Hepatitis C/HIV Coinfection in the Era of Highly Effective Hepatitis C Virus Direct-Acting Antiviral Therapy. Clin Infect Dis (2016) 0.78
Sustained Virologic Response at 24 Weeks after the End of Treatment Is a Better Predictor for Treatment Outcome in Real-World HCV-Infected Patients Treated by HCV NS3/4A Protease Inhibitors with Peginterferon plus Ribavirin. Int J Med Sci (2016) 0.78
A Budget Impact Analysis of Newly Available Hepatitis C Therapeutics and the Financial Burden on a State Correctional System. J Urban Health (2015) 0.78
Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection. Drug Des Devel Ther (2015) 0.78
Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and Ombitasvir. Antimicrob Agents Chemother (2015) 0.78
Ribavirin Contributes to Hepatitis C Virus Suppression by Augmenting pDC Activation and Type 1 IFN Production. PLoS One (2015) 0.78
Highlights of the Fourth Canadian Symposium on Hepatitis C: Moving towards a National Action Plan. Can J Gastroenterol Hepatol (2016) 0.78
Concise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection. World J Gastroenterol (2016) 0.78
Real-World Sustained Virologic Response Rates of Sofosbuvir-Containing Regimens in Patients Coinfected With Hepatitis C and HIV. Clin Infect Dis (2016) 0.78
Management of hepatitis C genotype 4 in the directly acting antivirals era. BMJ Open Gastroenterol (2016) 0.77
Breaking Down Barriers to Care in Hepatitis C Virus Infection. J Infect Dis (2015) 0.77
Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors - Results from the PAN Study. PLoS One (2016) 0.77
Patients with Haemoglobinopathies and Chronic Hepatitis C: A Real Difficult to Treat Population in 2016? Mediterr J Hematol Infect Dis (2017) 0.77
ITPA Polymorphisms Are Associated with Hematological Side Effects during Antiviral Therapy for Chronic HCV Infection. PLoS One (2015) 0.77
Coronaviruses resistant to a 3C-like protease inhibitor are attenuated for replication and pathogenesis, revealing a low genetic barrier but high fitness cost of resistance. J Virol (2014) 0.77
Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States: The quality-adjusted cost of care. Medicine (Baltimore) (2016) 0.77
The New Era of Interferon-Free Treatment of Chronic Hepatitis C. Viszeralmedizin (2015) 0.77
Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort. J Acquir Immune Defic Syndr (2017) 0.76
Psychosocial assessment and monitoring in the new era of non-interferon-alpha hepatitis C virus treatments. World J Hepatol (2015) 0.76
Evolution of hepatitis C virus quasispecies during repeated treatment with the NS3/4A protease inhibitor telaprevir. Antimicrob Agents Chemother (2015) 0.76
Era of direct acting antivirals in chronic hepatitis C: Who will benefit? World J Hepatol (2015) 0.76
Hepatitis C virus-HIV-coinfected patients and liver transplantation. Curr Opin Organ Transplant (2015) 0.76
Direct antiviral agent treatment of decompensated hepatitis C virus-induced liver cirrhosis. World J Gastrointest Pharmacol Ther (2015) 0.76
Paritaprevir/ritonavir-ombitasvir and dasabuvir, the 3D regimen for the treatment of chronic hepatitis C virus infection: a concise review. Hepat Med (2016) 0.76
Effect of Peginterferon or Ribavirin Dosing on Efficacy of Therapy With Telaprevir in Treatment-Experienced Patients With Chronic Hepatitis C and Advanced Liver Fibrosis: A Multicenter Cohort Study. Medicine (Baltimore) (2015) 0.75
The dollars and sense of chronic hepatitis C infection management. Can J Infect Dis Med Microbiol (2015) 0.75
Baseline quasispecies selection and novel mutations contribute to emerging resistance-associated substitutions in hepatitis C virus after direct-acting antiviral treatment. Sci Rep (2017) 0.75
HCV Kinetic Models and Their Implications in Drug Development. CPT Pharmacometrics Syst Pharmacol (2015) 0.75
Drug-Drug Interactions Among Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Medications. Infect Dis Ther (2015) 0.75
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med (2004) 16.21
Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med (2013) 13.30
Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet (2002) 12.16
Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA (2006) 11.71
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med (2014) 9.45
Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA (2010) 9.26
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med (2014) 9.25
Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA (2012) 8.94
Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med (2006) 8.57
Early liver transplantation for severe alcoholic hepatitis. N Engl J Med (2011) 8.50
Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol (2002) 8.21
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med (2014) 7.73
Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med (2008) 7.31
Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis (2008) 6.43
Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med (2005) 6.31
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med (2014) 6.31
ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res (2007) 5.75
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med (2014) 5.29
Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med (2002) 4.89
Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology (2008) 4.73
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50
Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis (2008) 4.47
Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells. J Exp Med (2004) 4.37
Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology (2007) 4.09
S phase activation of the histone H2B promoter by OCA-S, a coactivator complex that contains GAPDH as a key component. Cell (2003) 4.03
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology (2015) 3.96
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology (2006) 3.92
Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology (2007) 3.57
Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med (2013) 3.52
Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology (2004) 3.47
Anaphylaxis-a practice parameter update 2015. Ann Allergy Asthma Immunol (2015) 3.45
Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med (2009) 3.41
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med (2014) 3.40
Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis (2010) 3.37
Nonalcoholic fatty liver disease: diagnostic and fat-grading accuracy of low-flip-angle multiecho gradient-recalled-echo MR imaging at 1.5 T. Radiology (2009) 3.31
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis (2013) 3.30
Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: Evidence from a meta-analysis of individual participant data. Hepatology (2014) 3.30
Hospital admission is a relevant source of hepatitis C virus acquisition in Spain. J Hepatol (2007) 3.21
Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis (2013) 3.17
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med (2015) 3.16
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med (2015) 3.13
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med (2015) 3.13
Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc Natl Acad Sci U S A (2002) 3.11
Tenofovir DF plus lamivudine or emtricitabine for nonoccupational postexposure prophylaxis (NPEP) in a Boston Community Health Center. J Acquir Immune Defic Syndr (2008) 3.10
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol (2005) 3.10
An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med (2014) 3.04
The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology (2003) 3.00
The interleukin-17 pathway is involved in human alcoholic liver disease. Hepatology (2009) 2.92
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int (2011) 2.77
Atopic dermatitis: a practice parameter update 2012. J Allergy Clin Immunol (2013) 2.70
Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology (2008) 2.70
A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med (2009) 2.56
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med (2014) 2.54
First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline. J Viral Hepat (2002) 2.43
TIN2 binds TRF1 and TRF2 simultaneously and stabilizes the TRF2 complex on telomeres. J Biol Chem (2004) 2.36
Is it traffic type, volume, or distance? Wheezing in infants living near truck and bus traffic. J Allergy Clin Immunol (2005) 2.35
Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology (2010) 2.32
Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology (2014) 2.28
Diagnosis and management of work-related asthma: American College Of Chest Physicians Consensus Statement. Chest (2008) 2.27
Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol (2009) 2.22
Age-Specific prevalence of anal human papillomavirus infection in HIV-negative sexually active men who have sex with men: the EXPLORE study. J Infect Dis (2004) 2.21
Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nat Med (2009) 2.21
Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol (2003) 2.18
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med (2015) 2.17
Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology (2004) 2.17
Probiotics reduce gut microbial translocation and improve adult atopic dermatitis. J Clin Gastroenterol (2012) 2.15
Mathematical modeling of liver injury and dysfunction after acetaminophen overdose: early discrimination between survival and death. Hepatology (2012) 2.14
Prophylactic analgesia before percutaneous liver biopsy: a clinical comparative study. Eur J Gastroenterol Hepatol (2011) 2.13
Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. Ann Intern Med (2015) 2.13
AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. Blood (2006) 2.09
Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology (2010) 2.06
Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. Gastroenterology (2006) 2.05
Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. Hepatology (2014) 2.04
FBF-1 and FBF-2 regulate the size of the mitotic region in the C. elegans germline. Dev Cell (2004) 2.03
Hepatocellular carcinoma: stiffness value and ratio to discriminate malignant from benign focal liver lesions. Radiology (2015) 2.03
Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. Hepatology (2009) 2.02
Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis. J Infect Dis (2012) 2.00
African herbal medicines in the treatment of HIV: Hypoxis and Sutherlandia. An overview of evidence and pharmacology. Nutr J (2005) 1.99
Barriers to participating in an HIV vaccine trial: a systematic review. AIDS (2004) 1.97
The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology (2012) 1.97
Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity. Am J Physiol Gastrointest Liver Physiol (2005) 1.96
Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl (2004) 1.95
Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA (2013) 1.94